Compare Stocks: EIKN, SRPT, PHVS, and MESO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EIKN Eikon Therapeutics	$10.96 -3.7%	$10.65	$7.90 ▼ $17.40	$616.40M	N/A	502,077 shs	384,276 shs
MESO Mesoblast	$17.14 -0.9%	$15.87	$13.05 ▼ $21.50	$2.25B	2.12	215,224 shs	86,062 shs
PHVS Pharvaris	$35.66 +1.4%	$34.76	$20.65 ▼ $38.13	$2.30B	-2.33	673,549 shs	356,947 shs
SRPT Sarepta Therapeutics	$22.99 -0.9%	$18.15	$14.68 ▼ $25.32	$2.45B	0.27	3.02 million shs	2.77 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EIKN Eikon Therapeutics	-3.69%	-4.86%	+14.64%	+22.32%	+1,095,999,900.00%
MESO Mesoblast	-0.87%	-5.72%	+15.81%	+22.87%	+33.07%
PHVS Pharvaris	+1.39%	-3.62%	+5.28%	+14.70%	+62.76%
SRPT Sarepta Therapeutics	-0.95%	+6.48%	+40.27%	+45.97%	+21.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EIKN Eikon Therapeutics	$10.96 -3.7%	$10.65	$7.90 ▼ $17.40	$616.40M	N/A	502,077 shs	384,276 shs
MESO Mesoblast	$17.14 -0.9%	$15.87	$13.05 ▼ $21.50	$2.25B	2.12	215,224 shs	86,062 shs
PHVS Pharvaris	$35.66 +1.4%	$34.76	$20.65 ▼ $38.13	$2.30B	-2.33	673,549 shs	356,947 shs
SRPT Sarepta Therapeutics	$22.99 -0.9%	$18.15	$14.68 ▼ $25.32	$2.45B	0.27	3.02 million shs	2.77 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EIKN Eikon Therapeutics	-3.69%	-4.86%	+14.64%	+22.32%	+1,095,999,900.00%
MESO Mesoblast	-0.87%	-5.72%	+15.81%	+22.87%	+33.07%
PHVS Pharvaris	+1.39%	-3.62%	+5.28%	+14.70%	+62.76%
SRPT Sarepta Therapeutics	-0.95%	+6.48%	+40.27%	+45.97%	+21.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EIKN Eikon Therapeutics	2.38	Hold	$25.00	128.10% Upside
MESO Mesoblast	2.00	Hold	$39.00	127.54% Upside
PHVS Pharvaris	2.86	Moderate Buy	$51.08	43.23% Upside
SRPT Sarepta Therapeutics	2.20	Hold	$25.06	9.00% Upside

Current Analyst Ratings Breakdown

Latest EIKN, SRPT, PHVS, and MESO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	MESO Mesoblast	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$35.00 ➝ $39.00
8/21/2026	EIKN Eikon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/19/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/14/2026	PHVS Pharvaris	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$60.00
8/14/2026	PHVS Pharvaris	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$5.00 ➝ $4.00
8/13/2026	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/13/2026	PHVS Pharvaris	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight
8/13/2026	PHVS Pharvaris	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	PHVS Pharvaris	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$51.00 ➝ $52.00
8/13/2026	PHVS Pharvaris	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$74.00 ➝ $75.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	$8.61 per share	N/A
MESO Mesoblast	$120.25M	18.51	N/A	N/A	$4.38 per share	3.91
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.35 per share	N/A
SRPT Sarepta Therapeutics	$2.20B	1.10	N/A	N/A	$14.46 per share	1.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	-$57.50M	-$0.28	N/A	47.61	N/A	N/A	N/A	N/A	9/4/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	12.49	0.34	-13.48%	-1.60%	-0.66%	11/4/2026 (Estimated)

Latest EIKN, SRPT, PHVS, and MESO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million
7/31/2026	Q4 2026	MESO Mesoblast	N/A	-$0.0660	N/A	-$0.0660	N/A	$34.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EIKN Eikon Therapeutics	N/A	9.89	9.89
MESO Mesoblast	0.19	2.43	2.09
PHVS Pharvaris	N/A	11.94	11.94
SRPT Sarepta Therapeutics	0.55	4.42	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EIKN Eikon Therapeutics	N/A
MESO Mesoblast	1.43%
PHVS Pharvaris	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
EIKN Eikon Therapeutics	N/A
MESO Mesoblast	18.80%
PHVS Pharvaris	11.84%
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
MESO Mesoblast	80	129.88 million	105.46 million	Optionable
PHVS Pharvaris	30	65.41 million	57.66 million	Not Optionable
SRPT Sarepta Therapeutics	1,372	105.63 million	98.34 million	Optionable

EIKN, SRPT, PHVS, and MESO Headlines

Recent News About These Companies

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

September 3 at 11:29 AM | theglobeandmail.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 6.6% - Should You Buy?

September 2 at 12:40 PM | marketbeat.com

Empowered Funds LLC Acquires Shares of 190,586 Sarepta Therapeutics, Inc. $SRPT

September 2 at 4:15 AM | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

September 2 at 3:27 AM | marketbeat.com

70,233 Shares in Sarepta Therapeutics, Inc. $SRPT Purchased by Hsbc Holdings PLC

September 1 at 3:44 AM | marketbeat.com

Canada Pension Plan Investment Board Buys Shares of 70,800 Sarepta Therapeutics, Inc. $SRPT

September 1 at 3:43 AM | marketbeat.com

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

August 31, 2026 | businesswire.com

Legal & General Group Plc Takes Position in Sarepta Therapeutics, Inc. $SRPT

August 31, 2026 | marketbeat.com

Man Group plc Takes $7.16 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 30, 2026 | marketbeat.com

Freestone Grove Partners LP Acquires Shares of 76,629 Sarepta Therapeutics, Inc. $SRPT

August 30, 2026 | marketbeat.com

Jefferies Financial Group Inc. Takes $3.42 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 29, 2026 | marketbeat.com

Deutsche Bank AG Takes $2.04 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 29, 2026 | marketbeat.com

Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution

August 28, 2026 | seekingalpha.com

OMERS ADMINISTRATION Corp Takes $864,000 Position in Sarepta Therapeutics, Inc. $SRPT

August 28, 2026 | marketbeat.com

SRPT Poised for Biggest Rally in 5 Months as Late-2026 Clinical Data Sparks Retail Investors’ ‘Monumental Comeback’

August 27, 2026 | profitconfidential.comP

SRPT on track for best week in 5 months ahead of late-2026 clinical data — retail eyes monumental comeback

August 27, 2026 | msn.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 15.2% - What's Next?

August 27, 2026 | marketbeat.com

Ieq Capital LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes $17.49 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

BlackRock Inc. Takes $341.34 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN, SRPT, PHVS, and MESO Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

$10.96 -0.42 (-3.69%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$10.92 -0.04 (-0.32%)

As of 04:00 AM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

Mesoblast NASDAQ:MESO

$17.14 -0.15 (-0.87%)

As of 09/3/2026 04:00 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Pharvaris NASDAQ:PHVS

$35.66 +0.49 (+1.39%)

As of 09/3/2026 04:00 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Sarepta Therapeutics NASDAQ:SRPT

$22.99 -0.22 (-0.95%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$22.66 -0.33 (-1.46%)

As of 04:02 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EIKN, SRPT, PHVS, and MESO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EIKN, SRPT, PHVS, and MESO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EIKN, SRPT, PHVS, and MESO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN, SRPT, PHVS, and MESO Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

Mesoblast NASDAQ:MESO

Pharvaris NASDAQ:PHVS

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EIKN, SRPT, PHVS, and MESO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EIKN, SRPT, PHVS, and MESO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EIKN, SRPT, PHVS, and MESO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN, SRPT, PHVS, and MESO Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

Mesoblast NASDAQ:MESO

Pharvaris NASDAQ:PHVS

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools